The healthcare world involves new economics that are driving moves toward increased scale and lower margins.  Evolving regulatory policy creates a moving target that can present both challenges and opportunities.  Companies in the life sciences areas–such as pharmaceutical, medical device, and biotech–need assistance to adapt to systemic shifts, like changes in reimbursement systems, DNA-based personal medicine and efforts to contain costs.

Our Healthcare & Pharmaceuticals Group is adept at assessing and implementing strategic alternatives, reviewing business lines and operations, properly allocating costs, optimizing working capital and liquidity, improving vendor and supply chain terms and balance sheet restructurings.

Selected Engagements

We wish health and peace of mind all around in this difficult and chaotic time. Our thoughts are with those who are struggling with Covid-19 and its broad and painful effects.

Goldin Associates is fully operational, and you can continue to expect our customary level of client service.  Although the Covid-19 situation is unique, the commercial effects present the kind of challenges that we are accustomed to addressing.  As crisis management and restructuring professionals, whether as interim corporate officers or advisors, our team members are seasoned in helping management teams, creditors, equity holders and other constituents chart a steady course through turbulent waters.  As fiduciaries, we work to preserve value and as financial experts we measure it.  

We hope and pray that the disruptive health, social and economic effects of this crisis are as contained as possible, and we are striving to do what we can—as community members and as professionals—to work towards that goal.